Êîíòàêòû/Ïðîåçä  Äîñòàâêà è Îïëàòà Ïîìîùü/Âîçâðàò
Èñòîðèÿ
  +7(495) 980-12-10
  ïí-ïò: 10-18
  shop@logobook.ru
   
    Ïîèñê êíèã                    Ïîèñê ïî ñïèñêó ISBN Ðàñøèðåííûé ïîèñê    
Íàéòè
  Çàðóáåæíûå èçäàòåëüñòâà Ðîññèéñêèå èçäàòåëüñòâà  
Àâòîðû | Êàòàëîã êíèã | Èçäàòåëüñòâà | Íîâèíêè | Ó÷åáíàÿ ëèòåðàòóðà | Àêöèè | Cåðòèôèêàòû | Õèòû | | |
 

Drug Delivery Systems In Cancer Therapy, Brown, Dennis M.



Âàðèàíòû ïðèîáðåòåíèÿ
Öåíà: 31919ð.
Êîë-âî:
Íàëè÷èå: Ïîñòàâêà ïîä çàêàç.  Åñòü â íàëè÷èè íà ñêëàäå ïîñòàâùèêà.
Ñêëàä Àíãëèÿ: 82 øò.  Ñêëàä Àìåðèêà: 127 øò.  
Ïðè îôîðìëåíèè çàêàçà äî: 26 ìàé 2022
Îðèåíòèðîâî÷íàÿ äàòà ïîñòàâêè: Èþíü

Çàêàç ïîêà íåâîçìîæåí
â Ìîè æåëàíèÿ

Àâòîð: Brown, Dennis M.
Íàçâàíèå:  Drug Delivery Systems In Cancer Therapy
Ïåðåâîä íàçâàíèÿ: Äåííèñ Ì. Áðàóí: Ñíàáæåíèå ëåêàðñòâåííûìè ïðåïàðàòàìè ïðè ëå÷åíèè ðàêà
ISBN: 9780896038882
Èçäàòåëüñòâî: Springer
Êëàññèôèêàöèÿ:
ISBN-10: 0896038882
Îáëîæêà/Ôîðìàò: Hardback
Ñòðàíèöû: 400
Âåñ: 0.936 êã.
Äàòà èçäàíèÿ: 2004
Ñåðèÿ: Cancer Drug Discovery and Development
ßçûê: English
Èëëþñòðàöèè: 57 black & white illustrations, biography
Ðàçìåð: 25.76 x 18.14 x 2.79
×èòàòåëüñêàÿ àóäèòîðèÿ: Postgraduate, research & scholarly
Ññûëêà íà Èçäàòåëüñòâî: Link
Ðåéòèíã:
Ïîñòàâëÿåòñÿ èç: Ãåðìàíèè
Äîïîëíèòåëüíîå îïèñàíèå: Ôîðìàò: 254x178
Èëþñòðàöèè: 59
Êðóã ÷èòàòåëåé: Experimental oncologists, pharmacologists, medicinal chemists, oncologists, and clinical pharmacologists
Êëþ÷åâûå ñëîâà:
ßçûê: eng





Antifolate Drugs in Cancer Therapy

Àâòîð: Jackman Ann L.
Íàçâàíèå: Antifolate Drugs in Cancer Therapy
ISBN: 0896035964 ISBN-13(EAN): 9780896035966
Èçäàòåëüñòâî: Springer
Ðåéòèíã:
Öåíà: 34696 ð.
Íàëè÷èå íà ñêëàäå: Åñòü ó ïîñòàâùèêà Ïîñòàâêà ïîä çàêàç.

Îïèñàíèå: This collection of cutting-edge reviews comprehensively examines the current status of novel antifolates, an important class of anticancer drugs. The distinguished contributors discuss the preclinical and clinical pharmacology of methotrexate, other dihydrofolate reductase inhibitors, 5-fluorouracil, and the new generation of antifolates-the thymidylate synthase and glycinamide ribonucleotide formyltransferase inhibitors. In addition, they review in depth the modulation of antifolate drugs, folate and antifolate transport mechanisms, polyglutamation, resistance, and drug combinations, as well as pharmacogenomics, pharmacodynamics, regulation of gene expression, and mechanisms of cell death. Antifolate Drugs in Cancer Therapy provides entré to exciting new avenues for future research and constitutes a new standard reference for all basic scientists and clinicians engaged in cancer therapeutics.

Cellular Drug Delivery / Principles and Practice

Àâòîð: Lu D. Robert, Øie Svein
Íàçâàíèå: Cellular Drug Delivery / Principles and Practice
ISBN: 1588292541 ISBN-13(EAN): 9781588292544
Èçäàòåëüñòâî: Springer
Ðåéòèíã:
Öåíà: 27756 ð.
Íàëè÷èå íà ñêëàäå: Åñòü ó ïîñòàâùèêà Ïîñòàâêà ïîä çàêàç.

Îïèñàíèå: An authoritative and up-to-date survey of the fundamental principles, and practice of drug delivery at the cellular level. On the principles side, the authors discuss the broad spectrum of cellular delivery, ranging from coverage of cell-mediated immunity, gene delivery, and protein targeting, to cellular drug transport, cellular drug permeability, and a variety of carrier system related to targeted drug delivery. On the practice side, the authors focus on technological developments in cellular drug delivery, including novel formulations for the delivery of DNA and antisense oligonucleotides ,as well as drug targeting with immunoglobulin formulations and antibody-mediated approaches.

Ansel`s Pharmaceutical Dosage Forms and Drug Delivery Systems

Àâòîð: Allen, Loyd
Íàçâàíèå: Ansel`s Pharmaceutical Dosage Forms and Drug Delivery Systems
ISBN: 1469855682 ISBN-13(EAN): 9781469855684
Èçäàòåëüñòâî: Lippincott Williams & Wilkins
Ðåéòèíã:
Öåíà: 10890 ð.
Íàëè÷èå íà ñêëàäå: Ïîñòàâêà ïîä çàêàç.

Îïèñàíèå: Succeed in your course with the most comprehensive source on pharmaceutical dosage forms and drug delivery systems available today. Reflecting the CAPE, APhA, and NAPLEX® competencies, this trusted resource covers physical pharmacy, pharmacy practice, pharmaceutics, compounding, and dosage forms and the clinical application of the various dosing forms in patient care. The 10th edition features a dynamic new full color design, new coverage of prescription flavoring, and additional coverage of expiration dates.   See pharmaceutical concepts in action through the two case studies (one pharmaceutical and one clinical) in each dosing forms chapter. Practice applying material using the group and individual activities in Applying the Principles and Concepts sections in every chapter. Master important underlying pharmaceutical principles through Physical Pharmacy Capsules. Extend your learning beyond the book with the online glossary and the online quiz bank that features 300 NAPLEX-style questions.Focus on what’s important with Chapter Objectives that highlight key material you need to master.

Ansel`s pharmaceutical dosage forms and drug delivery systems

Íàçâàíèå: Ansel`s pharmaceutical dosage forms and drug delivery systems
ISBN: 0781779340 ISBN-13(EAN): 9780781779340
Èçäàòåëüñòâî: Lippincott Williams & Wilkins
Ðåéòèíã:
Öåíà: 8894 ð.
Íàëè÷èå íà ñêëàäå: Ïîñòàâêà ïîä çàêàç.

Îïèñàíèå: Suitable for pharmaceutics courses, this book provides a comprehensive source on pharmaceutical dosage forms and drug delivery systems. It features content that coincides with the CAPE, APhA, and NAPLEX competencies. It offers coverage that incorporates various dosage forms on the market and those in the US Pharmacopoeia-National Formulary.

Polymer Therapeutics I / Polymers as Drugs, Conjugates and Gene Delivery Systems

Àâòîð: Satchi-Fainaro Ronit, Duncan Ruth
Íàçâàíèå: Polymer Therapeutics I / Polymers as Drugs, Conjugates and Gene Delivery Systems
ISBN: 3540292101 ISBN-13(EAN): 9783540292104
Èçäàòåëüñòâî: Springer
Ðåéòèíã:
Öåíà: 42917 ð.
Íàëè÷èå íà ñêëàäå: Åñòü ó ïîñòàâùèêà Ïîñòàâêà ïîä çàêàç.

Îïèñàíèå: 1 Duncan, H. Ringsdorf, R. Satchi-Fainaro: Polymer Therapeutics: Polymers as Drugs, Drug and Protein Conjugates and Gene Delivery Systems: Past, Present and Future Opportunities.- 2 P.K. Dhal, S.R. Holmes-Farley, C.C. Huval, T.H. Jozefiak: Polymers as Drugs.- 3 R.J. Amir, D. Shabat: Domino Dendrimers.- 4 G. Pasut, F.M. Veronese: PEGylation of Proteins as Tailored Chemistry for Optimized Bioconjugates.- E. Wagner, J. Kloeckner: Gene Delivery Using Polymer Therapeutics.-  

Farnesyltransferase Inhibitors in Cancer Therapy

Àâòîð: Sebti Saïd M., Hamilton Andrew D.
Íàçâàíèå: Farnesyltransferase Inhibitors in Cancer Therapy
ISBN: 0896036294 ISBN-13(EAN): 9780896036291
Èçäàòåëüñòâî: Springer
Ðåéòèíã:
Öåíà: 23759 ð.
Íàëè÷èå íà ñêëàäå: Åñòü ó ïîñòàâùèêà Ïîñòàâêà ïîä çàêàç.

Îïèñàíèå: Cutting-edge researchers describe their efforts to design, synthesize, and evaluate the biological activities of farensyltransferase inhibitors (FTIs); geranylgeranyltransferase inhibitors (GGTIs) are also discussed as potential anticancer drugs. The authors survey in detail such inhibitors as CAAX box peptidomimetics, FPP mimics, and bisubstrate transition state analogs, and critically review their uses in combination with radiation and other cytotoxic agents, such as gemcitabine, cisplatin, and taxanes. Illuminating and richly detailed, Farnesyltransferase Inhibitors in Cancer Therapy constitutes today's standard reference for the pathbreaking use of FTIs and GGTIs in anticancer therapy and offers basic and clinical investigators a comprehensive treatment of the scientific and medical aspects of farnesyltransferase inhibitors. Signal Transduction Pathways: A Goldmine for Therapeutic Targets, Paul Workman. The Biochemistry of Farnesyltransferase and Geranylgeranyltransferase I, Chih-Chin Huang, Carol A. Fierke, and Patrick J. Casey. Structures of Protein Farnesyltransferase, Stephen B. Long and Lorena S. Beese. Peptidomimetic-Based Inhibitors of Farnesyltransferase, David Knowles, Jiazhi Sun, Saul Rosenberg, Saïd M. Sebti, and Andrew D. Hamilton. Antitumor Efficacy of a Farnesyltransferase Inhibitor in Transgenic Mice, Jackson B. Gibbs, Samuel L. Graham, George D. Hartman, Kenneth S. Koblan, Nancy E. Kohl, Charles Omer, Angel Pellicier, Jolene Windle, and Allen Oliff. Development of Farnesyltransferase Inhibitors as Potential Antitumor Agents, Veeraswamy Manne, Frank Lee, Ning Yan, Craig Fairchild, and William C. Rose. Tricyclic Farnesyl Protein Transferase Inhibitors: Antitumor Activity and Effects on Protein Prenylation, W. Robert Bishop, James J.-K. Pai, Lydia Armstrong, Marguerite B. Dalton, Ronald J. Doll, Arthur Taveras, George Njoroge, Michael Sinensky, Fang Zhang, Ming Liu, and Paul Kirschmeier. Histidylbenzylglycinamides: A Novel Class of Farnesyl Diphosphate-Competitive Peptidic Farnesyltransferase Inhibitors, Judith S. Sebolt-Leopold, Daniele M. Leonard, and W. R. Leopold. From Random Screening of Chemical Libraries to the Optimization of FPP-Competitive Inhibitors of Farnesyltransferase, Patrick Mailliet, Abdel Laoui, Jean-Dominique Bourzat, Marc Capet, Michel Chevé, Alain Commerçon, Norbert Dereu, Alain LeBrun, Jean-Paul Martin, Jean-François Peyronel, Christophe Salagnad, Fabienne Thompson, Martine Zucco, Jean-Dominique Guitton, Guy Pantel, Marie-Christine Bissery, Clive Brealey, Jacques Lavayre, Yves Lelièvre, Jean-François Riou, Patricia Vrignaud, Marc Duchesne, and François Lavelle. Genetic Analysis of FTase and GGTase I and Natural Product Farnesyltransferase Inhibitors, Fuyuhiko Tamanoi, Keith Del Villar, Nicole Robinson, MeeRhan Kim, Jun Urano, and Wenli Yang. Effects of Farnesyltransferase Inhibitors on Cytoskeleton, Cell Transformation, and Tumorigenesis: The FTI-Rho Hypothesis, George C. Prendergast. Prenyltransferase Inhibitors as Radiosensitizers, Eric J. Bernhard, Ruth J. Muschel, Elizabeth Cohen-Jonathan, Gilles Favre, Andrew D. Hamilton, Saïd M. Sebti, and W. Gillies McKenna. Farnesyltransferase and Geranylgeranyltransferase I Inhibitors as Novel Agents for Cancer and Cardiovascular Diseases, Saïd M. Sebti and Andrew D. Hamilton. Protein Prenylation in Trypanosomatids: A New Piggy-Back Medicinal Chemistry Target for the Development of Agents Against Tropical Diseases, Michael H. Gelb, Frederick S. Buckner, Kohei Yokoyama, Junko Ohkanda, Andrew D. Hamilton, Lisa Nguyen, Bartira Rossi-Bergmann, Kenneth D. Stuart, Saïd M. Sebti, and Wesley C. Van Voorhis. Early Clinical Experience with Farnesyl Protein Transferase Inhibitors: From the Bench to the Bedside, Amita Patnaik and Eric K. Rowinsky. Phase I Trial of Oral R115777 in Patients with Refractory Solid Tumors: Preliminary Results, Gary R. Hudes and Jessie Schol. Farnesyltransferase and Geranylgeranyltransferase Inhibitors: The Saga Continues, Adrienne D. Cox, L. Gerard Toussaint III, James J. Fiordalisi, Kelley Rogers-Graham, and Channing J. Der. Index.

Antiangiogenic Agents in Cancer Therapy

Àâòîð: Teicher Beverly A.
Íàçâàíèå: Antiangiogenic Agents in Cancer Therapy
ISBN: 0896036413 ISBN-13(EAN): 9780896036413
Èçäàòåëüñòâî: Springer
Öåíà: 20783 ð.
Íàëè÷èå íà ñêëàäå: Íåò â íàëè÷èè.

Tumor Targeting in Cancer Therapy

Àâòîð: Pagé Michel
Íàçâàíèå: Tumor Targeting in Cancer Therapy
ISBN: 0896039196 ISBN-13(EAN): 9780896039193
Èçäàòåëüñòâî: Springer
Ðåéòèíã:
Öåíà: 36977 ð.
Íàëè÷èå íà ñêëàäå: Åñòü ó ïîñòàâùèêà Ïîñòàâêà ïîä çàêàç.

Îïèñàíèå: In Tumor Targeting in Cancer Therapy, Dr. Michel Pagé and a panel of authoritative experts from the drug industry, clinics, and academia introduce the principles and techniques of tumor targeting and critically survey their applications from laboratory to bedside. By concisely synthesizing the many technical details, the authors illuminate this innovative technique, ranging from the fundamentals of drug targeting and in vivo and in vitro experimentation, to such emerging therapeutic uses as radioimmunotherapy, radioimmunodetection, therapy with cytotoxic antibodies, immunotoxins, enzyme prodrug immunotherapy, and immunotherapeutics with fusion proteins. There are also reviews of targeting tumors with radioimmunoconjugates, photodynamic therapy, and magnetic drugs, as well as discussions of the internalization of antibodies, bioconjugation and biodistribution, the use of cytotoxic drugs, and the pros and cons of targeting by antibody or ligand.

Cell Cycle Inhibitors in Cancer Therapy

Àâòîð: Giordano Antonio, Soprano Kenneth J.
Íàçâàíèå: Cell Cycle Inhibitors in Cancer Therapy
ISBN: 0896039307 ISBN-13(EAN): 9780896039308
Èçäàòåëüñòâî: Springer
Ðåéòèíã:
Öåíà: 34007 ð.
Íàëè÷èå íà ñêëàäå: Åñòü ó ïîñòàâùèêà Ïîñòàâêà ïîä çàêàç.

Îïèñàíèå: Leading clinicians and investigators review in a comprehensible and user-friendly style all the latest information about the molecular biology of cell cycle control and demonstrate its clinical relevance to understanding neoplastic diseases. Topics range from Cdk inhibitors and cell cycle regulators to the prognostic value of p27 and tumor suppressor genes as diagnostic tools. Actual case studies show how the new molecular understanding has produced such drugs as Flavopiridol and Sulindac. The book brings all the recent critical research findings to bear on clinical practice, and clearly shows their powerful impact on the diagnostics, prognostics, and therapeutics of cancer, AIDS, and cardiovascular disease.

Proteasome Inhibitors in Cancer Therapy

Àâòîð: Adams Julian
Íàçâàíèå: Proteasome Inhibitors in Cancer Therapy
ISBN: 1588292509 ISBN-13(EAN): 9781588292506
Èçäàòåëüñòâî: Springer
Ðåéòèíã:
Öåíà: 34007 ð.
Íàëè÷èå íà ñêëàäå: Åñòü ó ïîñòàâùèêà Ïîñòàâêà ïîä çàêàç.

Îïèñàíèå: A panel of leading academic and pharmaceutical investigators takes stock of the remarkable work that has been accomplished to date with proteasome inhibitors in cancer, and examines emerging therapeutic possibilities. The topics range from a discussion of the chemistry and cell biology of the proteasome and the rationale for proteasome inhibitors in cancer to a review of current clinical trials underway. The discussion of rationales for testing proteasome inhibitors in cancer models covers the role of the proteasome in NF-kB activation, the combining of conventional chemotherapy and radiation with proteasome inhibition, notably PS-341, new proteasome methods of inhibiting viral maturation, and the role of protesome inhibition in the treatment of AIDS. The authors also document the development of bortezomib (Velcadeâ„¢) in Phase I clinical trials and in a multicentered Phase II clinical trials in patients with relapsed and refractory myeloma.

Optimization of Aerosol Drug Delivery

Àâòîð: Gradon Leon, Marijnissen J.C.
Íàçâàíèå: Optimization of Aerosol Drug Delivery
ISBN: 1402016514 ISBN-13(EAN): 9781402016516
Èçäàòåëüñòâî: Springer
Ðåéòèíã:
Öåíà: 42917 ð.
Íàëè÷èå íà ñêëàäå: Åñòü ó ïîñòàâùèêà Ïîñòàâêà ïîä çàêàç.

Îïèñàíèå: Aerosol therapy has significantly improved the treatment of a variety of respiratory diseases. Besides the treatment of respiratory diseases there is currently also a great interest to use the lungs as a portal to introduce drugs for systemic therapy. The success of therapy with the application of aerosolized medicaments depends on the possibility to deliver the proper amount of drug to the appropriate sites in the respiratory system, thus limiting the side effects to a minimum. Aerosolized delivery of drugs to the lung is optimized if, for a given chemical composition of a medicine, the target of deposition and the required mass of drug to be deposited are precisely defined. The next step is the specification of the number of respirable particles or droplets, to be generated by appropriate devices. Another very important factor for successful aerosol therapy is the condition of the patient coupled with his or her inhalation technique.

Surfactants & Polymers In Drug Delivery

Àâòîð: Malmsten Martin
Íàçâàíèå: Surfactants & Polymers In Drug Delivery
ISBN: 0824708040 ISBN-13(EAN): 9780824708047
Èçäàòåëüñòâî: Informa
Ðåéòèíã:
Öåíà: 27116 ð.
Íàëè÷èå íà ñêëàäå: Åñòü ó ïîñòàâùèêà Ïîñòàâêà ïîä çàêàç.

Îïèñàíèå: This reference features the latest findings surrounding the physicochemical aspects of surfactant and polymer systems to facilitate the design and understanding of novel and advanced drug delivery formulations. It covers the basics of surfactant and polymer surface activity and self-assembly, the various types of structures formed by such compounds, and how they may be used in drug delivery. It also discusses solubilization of drugs in micellar systems, liquid crystalline phases formed by PEO-PPO-PEO block copolymers and other copolymers and surfactants, triggered drug-release from liposome formulations, microemulsions formed by ionic and nonionic surfactants, and much more.


ÎÎÎ "Ëîãîñôåðà " Òåë:+7(495) 980-12-10 www.logobook.ru
   Â Êîíòàêòå     Â Êîíòàêòå Ìåä  Ìîáèëüíàÿ âåðñèÿ